(1) Background: Neurogranin is a post-synaptic protein expressed in the neurons of the hippocampus and cerebral cortex. It has been recently proposed as a promising biomarker of synaptic dysfunction, especially in Alzheimer’s disease (AD). However, more efforts are needed before intro- ducing it in clinical practice, including the definition of its reference interval (RI). The aim of the study was to establish the RI of cerebrospinal fluid (CSF) neurogranin levels in controls and individuals with non-neurodegenerative neurological diseases; (2) We included a total of 136 individuals that were sub-grouped as follows: AD patients (n = 33), patients with non-neurodegenerative neurological diseases (n = 70) and controls (33). We measured CSF neurogranin levels by a commercial ELISA kit. CSF RI of neurogranin was calculated by a robust method; (3) Results: AD patients showed increased levels of neurogranin. We also found that neurogranin was significantly correlated with T-tau, P-tau and mini mental state examination in AD patients. The lower and upper reference limits of the RI were 2.9 (90%CI 0.1–10.8) and 679 (90%CI 595–779), respectively; (4) Conclusion: This is the first study establishing the RI of CSF neurogranin.

Agnello, L., Lo Sasso, B., Vidali, M., Scazzone, C., Piccoli, T., Gambino, C.M., et al. (2021). Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease. DIAGNOSTICS, 11(12), 2339 [10.3390/diagnostics11122339].

Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease

Agnello, Luisa;Lo Sasso, Bruna;Scazzone, Concetta;Piccoli, Tommaso;Gambino, Caterina Maria;Bivona, Giulia;Giglio, Rosaria Vincenza;Ciaccio, Anna Maria;La Bella, Vincenzo;Ciaccio, Marcello
2021-12

Abstract

(1) Background: Neurogranin is a post-synaptic protein expressed in the neurons of the hippocampus and cerebral cortex. It has been recently proposed as a promising biomarker of synaptic dysfunction, especially in Alzheimer’s disease (AD). However, more efforts are needed before intro- ducing it in clinical practice, including the definition of its reference interval (RI). The aim of the study was to establish the RI of cerebrospinal fluid (CSF) neurogranin levels in controls and individuals with non-neurodegenerative neurological diseases; (2) We included a total of 136 individuals that were sub-grouped as follows: AD patients (n = 33), patients with non-neurodegenerative neurological diseases (n = 70) and controls (33). We measured CSF neurogranin levels by a commercial ELISA kit. CSF RI of neurogranin was calculated by a robust method; (3) Results: AD patients showed increased levels of neurogranin. We also found that neurogranin was significantly correlated with T-tau, P-tau and mini mental state examination in AD patients. The lower and upper reference limits of the RI were 2.9 (90%CI 0.1–10.8) and 679 (90%CI 595–779), respectively; (4) Conclusion: This is the first study establishing the RI of CSF neurogranin.
https://www.mdpi.com/2075-4418/11/12/2339
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700711/
Agnello, L., Lo Sasso, B., Vidali, M., Scazzone, C., Piccoli, T., Gambino, C.M., et al. (2021). Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease. DIAGNOSTICS, 11(12), 2339 [10.3390/diagnostics11122339].
File in questo prodotto:
File Dimensione Formato  
Neurogranin as a Reliable Biomarker for Synaptic Dysfunction.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 652.86 kB
Formato Adobe PDF
652.86 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/556688
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact